Implantable cardioverter defibrillator following acute myocardial infarction: the '48-hour' and '40-day' rule.

Evolution of left ventricular ejection fraction after acute myocardial infarction: implications for implantable cardioverter-defibrillator eligibility.

BACKGROUND Implantable cardioverter-defibrillator therapy improves survival in patients with reduced left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI). Although the risk of sudden cardiac death is highest in the first month after AMI, there is no survival benefit of early implantable cardioverter-defibrillator implantation, and the optimal time frame has yet to b...

Evolution of Left Ventricular Ejection Fraction After Acute Myocardial Infarction: Implications for Implantable Defibrillator Eligibility Running title: Sjöblom et al.; ICD early after myocardial infarction

Evolution of Left Ventricular Ejection Fraction After Acute Myocardial Infarction: Implications for Implantable Defibrillator Eligibility

Background—ICD therapy improves survival in patients with reduced left ventricular ejection

THE EFFECT OF NURSE-PEER-LED SUPPORT INTERVENTION ON QUALITY OF LIFE IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR: A RANDOMIZED CLINICAL TRIAL

Background & Aims: Nowadays, the quality of life and how coping and treatment of patients with an implantable cardiac defibrillator has led to concern and attempts to reduce or eliminate the problems of these patients in the people who provide health care services. This study aimed to determine the effect of nurse-peer-led support intervention on quality of life in patients with an implantable ...

Azimilide: another effort to prevent implantable cardioverter-defibrillator shocks and their sequelae why it is important and how it works.

ver the past decade, a series of randomized clinical trials sing the implantable cardioverter-defibrillator (ICD) have emonstrated a reduced mortality compared with that of the est medical therapy in selected populations with ejection raction (EF) 40%. Only patients with a low EF due to ecent acute myocardial infarction or recent coronary bypass urgery do not benefit as seen in prior trials. Su...